Takeda M, Shimokawa M, Nakamura A, Nosaki K, et al. Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platin Lung Cancer 2024 Jun 17:107852. doi: 10.1016/j.lungcan.2024.107852.
PMID: 38890056